News
Why Vaxxinity Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
22 Apr 24
News, Intraday Update, Markets, Movers
Inhibikase Therapeutics Issues Letter To Shareholders And Provides Update On Development Programs; Says 201 Trial Is ~75% Enrolled
18 Apr 24
News, Guidance, Management
Inhibikase Therapeutics Q4 EPS $(0.64) Beats $(0.85) Estimate, Sales $1.00K Down From $63.57K YoY
27 Mar 24
Earnings, News
HC Wainwright & Co. Reiterates Buy on Inhibikase Therapeutics, Maintains $27 Price Target
7 Mar 24
News, Price Target, Reiteration, Analyst Ratings
HC Wainwright & Co. Maintains Buy Rating for Inhibikase Therapeutics: Here's What You Need To Know
5 Mar 24
Analyst Ratings
HC Wainwright & Co. Maintains Buy on Inhibikase Therapeutics, Maintains $27 Price Target
5 Mar 24
News, Price Target, Analyst Ratings
Inhibikase Therapeutics Announces Full Outcomes Of Its Pre-NDA Meeting With The FDA For IkT-001Pro
28 Feb 24
Biotech, News, FDA, General
12 Health Care Stocks Moving In Friday's Intraday Session
26 Jan 24
Movers
12 Health Care Stocks Moving In Thursday's Intraday Session
25 Jan 24
Movers
Press releases
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
18 Apr 24
Health Care, Press Releases
Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension
3 Apr 24
News, Press Releases
Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity
27 Mar 24
Earnings, Press Releases
Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders
7 Mar 24
News, Health Care, Press Releases
Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers
7 Feb 24
Health Care, Press Releases, General
Nasdaq Stocks Above $2 to Watch Now! LVTX, INBS, IKT, PCSA, DYAI
29 Jan 24
News, Press Releases
Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib
29 Jan 24
Health Care, Press Releases, General